Glycopyrronium Tosylate Production Cost Reports

The report provides a detailed analysis essential for establishing a Glycopyrronium Tosylate production plant. It encompasses all critical aspects necessary for Glycopyrronium Tosylate production, including the cost of Glycopyrronium Tosylate production, Glycopyrronium Tosylate plant cost, Glycopyrronium Tosylate production costs, and the overall Glycopyrronium Tosylate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Glycopyrronium Tosylate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Glycopyrronium tosylate (brand name Qbrexza in the US) is a topical prescription medication utilised in the pharmaceutical industry as a topical anticholinergic agent for the treatment of primary axillary hyperhidrosis, a condition characterised by excessive underarm sweating.

It effectively inhibits sweat gland activity with formulations like QBREXZA cloths (2.4% concentration) approved for patients aged 9 and older. It shows significant sweat reduction (up to 107.6 mg/5 min) and improved severity scores in trials such as ATMOS-1 and ATMOS-2 after four weeks of daily application, along with mild side effects like dry mouth and local irritation. Its delivery system minimises systemic absorption, which makes it suitable for targeted dermatological applications.

The market demand for Glycopyrronium tosylate is propelled by the rising prevalence of respiratory disorders like COPD and asthma, coupled with expanding applications in hyperhidrosis treatment and preoperative care. Advancements in drug delivery systems, such as inhalation solutions, dry powder inhalers, and topical formulations like QBREXZA cloths, enhance efficacy and patient compliance, further boosting adoption in hospitals, clinics, and ambulatory centres.

However, technical specifications, such as microbial limits for non-sterile API and stability for monohydrate forms, as well as geopolitical risks and third-party dependency, impact industrial glycopyrronium tosylate procurement. Furthermore, fluctuations in the costs and availability of the major raw materials, such as p-toluenesulfonic acid and sodium hydroxide, also influence the overall sourcing.

Raw Material for Glycopyrronium Tosylate Production

According to the Glycopyrronium Tosylate production plant project report, the various raw materials for Glycopyrronium Tosylate production include p-toluenesulfonic acid and sodium hydroxide.

Production Process of Glycopyrronium Tosylate

The extensive Glycopyrronium Tosylate production cost report consists of the following major industrial production process:

1. Production via a two-step aqueous process: The production process of Glycopyrronium tosylate occurs via a two-step aqueous process. In the first step, p-toluenesulfonic acid undergoes neutralisation with a base (e.g., NaOH) at 20–25 degree Celsius in a single-phase water/organic medium to form the tosylate salt solution. In the second step, the salt is reacted with glycopyrronium bromide in another aqueous medium at ambient temperature for hours, enabling anion exchange. Finally, the product is isolated via filtration/centrifugation, followed by washing and crystallisation from water to yield pure Glycopyrronium tosylate.

Properties of Glycopyrronium Tosylate

Glycopyrronium tosylate appears as a white to off-white crystalline powder in monohydrate form (Form D), with molecular formula C26H37NO7S, and a molecular weight of 507.6 g/mol. It has two chiral centres producing diastereomers, a topological polar surface area of 113 Ų, one hydrogen bond donor, and multiple acceptors that enhance aqueous solubility and stability during crystallisation in systems like acetone-water-toluene. Additionally, as a quaternary ammonium salt, it has low systemic absorption due to polarity, bulk density over 0.4 g/cm³ in optimised 150–200 µm needle crystals for production filtration, and stability in neutral aqueous media requiring water activity ≥0.6 to avoid anhydrous polymorphs.